Evaluation of 3′,4′-cyclopropyl monomers for oligonucleotide therapeutic applications
vitro snake venom phosphodiesterase (SVPD) assays demonstrated that Cp-modified ASOs exhibit significantly enhanced nuclease resistance over the unmodified parent sequence, sometimes providing near-complete protection. This differential effect on stability and potency across the different oligonucleotide lengths and modalities warrants further investigation to fully delineate the mechanism of action of these modifications and to further optimize their application in therapeutic oligonucleotide design. Here, based on these results, we propose Cp monomers as a novel class of molecules for oligonucleotide therapeutic applications.
Authors
- Santhosh Kumar Thatikonda (ORCID: https://orcid.org/0009-0002-9337-9672)
- Jinsen Chen (ORCID: https://orcid.org/0009-0007-2084-236X)
- Steven Chin (ORCID: https://orcid.org/0000-0002-0807-9097)
- Seetha S. Krishnamoorthy
- Molly S. Blevins (ORCID: https://orcid.org/0000-0001-7423-2099)
- Aditi Dubey (ORCID: https://orcid.org/0000-0003-0162-7334)
- Yi‐Ju Tseng (ORCID: https://orcid.org/0000-0002-2242-6200)
- Yongfeng Yang
- Sumit Mahajan
- Han Nguyen
- Xiaoshuai Fan
- Jeff Cheng-Wei Lin
- Andrew Watkins
- Kayon Colao
Institutions
- Genentech (US)
Publication Details
- Journal
- Organic & Biomolecular Chemistry
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1039/d6ob01291d
- Primary Topic
- DNA and Nucleic Acid Chemistry
- Type
- article
- Field-Weighted Citation Impact
- 0.00